( tcome. To confirm the effectsof the no...)Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia,Health

tcome. To confirm the effects of the novel RNA Antagonist SPC2996 on Bcl-2 levels in CLL patients, Bcl-2 mRNA levels were determined in extracted RNA from blood samples from patients in this study. As shown in figure 2 attached, there was a statistically significant down regulation of Bcl-2 mRNA (expressed as a ratio to 18S ribosomal RNA, a measure of total blood RNA) in patients receiving drug at 4mg/kg/infusion, over the 2 week course of therapy. Such patient data supports the view that SPC2996 is working through specific antagonism of Bcl-2 mRNA.

Safety

SPC2996 was well tolerated. All infusions were unproblematic and there were no signs of cytokine release or complement activation. Two patients had rises in serum alanine aminotransferase (ALT) following the last dose (i.e. after a total dose of 24mg/kg) which were transient and the patients recovered fully. Two cases of grade 3 thrombocytopaenia were reported. In the 2mg/kg/infusion group, one patient was diagnosed to have Tumour Lysis Syndrome following 2 infusions of drug.

- ENDS -

Annabel Entress Account Manager ----------------------------------------------------------------------------------------------- Direct line: +44 (0)20 7268 3234 Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102 www.northbankcommunications.com <http://www.northbankcommunications.com>

Northbank Communications Ltd 85 Tottenham Court Road, London, W1T 4TQ UK

To see our latest newsletter, Newsbank, please click here <http://www.northbankcommunications.com/newsletter/newsletter.htm> .

This email and any attachments are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient you must not copy this
'"/>

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis